Whole goat milk versus cow milk formula and atopic dermatitis in infants: A randomized clinical trial
- Journal
- Clinical Nutrition (Q1)
- Published
- 3 June 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Veit Grote, Laura Schlosser, Cristina Campoy, Elena Crehuá-Gaudiza, Hans Demmelmair, Markus J Ege, et al.
- PMID
- 42275985
- DOI
- 10.1016/j.clnu.2026.106707
Why clinicians should know about it
- Picked for Dermatology (top studies of the week, 22 November 2026): Randomized trial, atopic dermatitis infant formula
Abstract
BACKGROUND AND AIMS: Atopic dermatitis (AD) poses a substantial burden on affected children and their families. The evidence of the role of feeding choices in infancy for AD development is limited. METHODS: This study is a two-arm, parallel, randomized, double-blind, controlled trial to assess the effect of infant feeding with whole goat milk formula (WGF) versus cow milk formula (CF) on AD development during the first year of life. Healthy term infants up to 3 months of age were enrolled in 6 Spanish and 4 Polish study centres, without AD risk selection. The primary outcome measure was AD diagnosed by study personnel at three study visits using the United Kingdom Working Party diagnostic criteria (ADPrimary). Reported doctor-diagnosed AD (ADDoctor) was a secondary outcome. Cumulative incidence in the first year of life was calculated. Incidence rate ratios (IRR) were estimated by Poisson regression. RESULTS: Data from 2132 infants were analyzed. 192 infants were diagnosed with ADPrimary and 245 with ADDoctor. The cumulative incidence rate of ADPrimary for both groups was 11.6 per 100 person-years without difference between WGF and CF (IRR: 1.00; 95%CI: 0.75, 1.32; p = 0.991). In the per-protocol population, the incidence of ADDoctor was lower in WGF than CF (IRR: 0.66; 95%CI: 0.49, 0.9; p = 0.008). In infants with parental history of AD, the protective effect of WGF was stronger: ADDoctor IRR 0.36 (95%CI: 0.17, 0.76; p = 0.007). CONCLUSION: This trial demonstrates that WGF can reduce the incidence of AD in formula-fed infants in the first year of life, especially in presence of parental history of AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04599946. Submitted: 2020-10-05.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.